{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T12:50:45Z","timestamp":1774356645864,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":63,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Natural Science Foundation of Shandong Province","award":["grant ZR2021QH050"],"award-info":[{"award-number":["grant ZR2021QH050"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"DOI":"10.1186\/s13048-026-01967-5","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T11:55:09Z","timestamp":1768910109000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Recurrent patterns and prognostic factors based on CA-125 and RECIST progression in ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors"],"prefix":"10.1186","volume":"19","author":[{"given":"Bingxin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiwei","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaojing","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiale","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinxi","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuhong","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hualei","family":"Bu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"issue":"2","key":"1967_CR1","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","volume":"21","author":"GJ Rustin","year":"2011","unstructured":"Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the gynecological cancer intergroup (GCIG). Int J Gynecol Cancer. 2011;21(2):419\u201323.","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"1967_CR2","doi-asserted-by":"publisher","first-page":"851","DOI":"10.2214\/ajr.167.4.8819370","volume":"167","author":"KD Hopper","year":"1996","unstructured":"Hopper KD, Kasales CJ, Van Slyke MA, Schwartz TA, TenHave TR, Jozefiak JA. Analysis of interobserver and intraobserver variability in CT tumor measurements. AJR Am J Roentgenol. 1996;167(4):851\u20134.","journal-title":"AJR Am J Roentgenol"},{"issue":"10","key":"1967_CR3","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1054\/bjoc.2001.1787","volume":"84","author":"MK Tuxen","year":"2001","unstructured":"Tuxen MK, Soletormos G, Dombernowsky P. Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy. Br J Cancer. 2001;84(10):1301\u20137.","journal-title":"Br J Cancer"},{"issue":"1","key":"1967_CR4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1200\/JCO.2005.01.2757","volume":"24","author":"GJ Rustin","year":"2006","unstructured":"Rustin GJ, Timmers P, Nelstrop A, Shreeves G, Bentzen SM, Baron B, et al. Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and Paclitaxel versus cisplatin and cyclophosphamide. J Clin Oncol. 2006;24(1):45\u201351.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1967_CR5","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/bjc.2011.593","volume":"106","author":"J Alexandre","year":"2012","unstructured":"Alexandre J, Brown C, Coeffic D, Raban N, Pfisterer J, Maenpaa J, et al. CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial. Br J Cancer. 2012;106(4):633\u20137.","journal-title":"Br J Cancer"},{"issue":"4","key":"1967_CR6","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1093\/oxfordjournals.annonc.a010602","volume":"7","author":"GJ Rustin","year":"1996","unstructured":"Rustin GJ, Nelstrop AE, Tuxen MK, Lambert HE. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames ovary group study. Ann Oncol. 1996;7(4):361\u20134.","journal-title":"Ann Oncol"},{"issue":"20","key":"1967_CR7","doi-asserted-by":"publisher","first-page":"4054","DOI":"10.1200\/JCO.2001.19.20.4054","volume":"19","author":"GJ Rustin","year":"2001","unstructured":"Rustin GJ, Marples M, Nelstrop AE, Mahmoudi M, Meyer T. Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol. 2001;19(20):4054\u20137.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1967_CR8","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ygyno.2019.10.023","volume":"156","author":"SC Cecere","year":"2020","unstructured":"Cecere SC, Giannone G, Salutari V, Arenare L, Lorusso D, Ronzino G, et al. Olaparib as maintenance therapy in patients with BRCA 1\u20132 mutated recurrent platinum sensitive ovarian cancer: real world data and post progression outcome. Gynecol Oncol. 2020;156(1):38\u201344.","journal-title":"Gynecol Oncol"},{"issue":"25","key":"1967_CR9","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2019","unstructured":"Gonz\u00e1lez-Mart\u00edn A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381(25):2391\u2013402.","journal-title":"N Engl J Med"},{"issue":"25","key":"1967_CR10","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard I, Pautier P, Pignata S, Perol D, Gonzalez-Martin A, Berger R, et al. Olaparib plus bevacizumab as First-Line maintenance in ovarian cancer. N Engl J Med. 2019;381(25):2416\u201328.","journal-title":"N Engl J Med"},{"key":"1967_CR11","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ejca.2020.08.021","volume":"139","author":"A Tjokrowidjaja","year":"2020","unstructured":"Tjokrowidjaja A, Lee CK, Friedlander M, Gebski V, Gladieff L, Ledermann J, et al. Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with Olaparib as maintenance therapy after response to chemotherapy. Eur J Cancer. 2020;139:59\u201367.","journal-title":"Eur J Cancer"},{"issue":"5","key":"1967_CR12","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1093\/annonc\/mdz062","volume":"30","author":"N Colombo","year":"2019","unstructured":"Colombo N, Sessa C, du Bois A, Ledermann J, McCluggage WG, McNeish I, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent diseasedagger. Ann Oncol. 2019;30(5):672\u2013705.","journal-title":"Ann Oncol"},{"issue":"10 Suppl","key":"1967_CR13","doi-asserted-by":"publisher","first-page":"s187","DOI":"10.1200\/JCO.2003.01.223","volume":"21","author":"GJ Rustin","year":"2003","unstructured":"Rustin GJ. Use of CA-125 to assess response to new agents in ovarian cancer trials. J Clin Oncol. 2003;21(10 Suppl):s187\u201393.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1967_CR14","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1200\/JCO.23.01182","volume":"42","author":"A Tjokrowidjaja","year":"2024","unstructured":"Tjokrowidjaja A, Friedlander ML, Ledermann JA, Coleman RL, Mirza MR, Matulonis UA, et al. Poor concordance between cancer Antigen-125 and RECIST assessment for progression in patients with Platinum-Sensitive relapsed ovarian cancer on maintenance therapy with a Poly(ADP-ribose) polymerase inhibitor. J Clin Oncol. 2024;42(11):1301\u201310.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1967_CR15","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/cas.12890","volume":"107","author":"M Yamamoto","year":"2016","unstructured":"Yamamoto M, Tsujikawa T, Fujita Y, Chino Y, Kurokawa T, Kiyono Y, et al. Metabolic tumor burden predicts prognosis of ovarian cancer patients who receive platinum-based adjuvant chemotherapy. Cancer Sci. 2016;107(4):478\u201385.","journal-title":"Cancer Sci"},{"issue":"1","key":"1967_CR16","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.ygyno.2006.07.027","volume":"104","author":"MM Juretzka","year":"2007","unstructured":"Juretzka MM, Barakat RR, Chi DS, Iasonos A, Dupont J, Abu-Rustum NR, et al. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy. Gynecol Oncol. 2007;104(1):176\u201380.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"1967_CR17","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.ygyno.2012.12.024","volume":"129","author":"T Levy","year":"2013","unstructured":"Levy T, Weiser R, Boaz M, Ben Shem E, Golan A, Menczer J. The significance of the pattern of serum CA125 level ascent to above the normal range in epithelial ovarian, primary peritoneal and tubal carcinoma patients. Gynecol Oncol. 2013;129(1):165\u20138.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"1967_CR18","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.ygyno.2011.02.020","volume":"121","author":"C Th\u00e9riault","year":"2011","unstructured":"Th\u00e9riault C, Pinard M, Comamala M, Migneault M, Beaudin J, Matte I, et al. MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis. Gynecol Oncol. 2011;121(3):434\u201343.","journal-title":"Gynecol Oncol"},{"key":"1967_CR19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1476-4598-9-11","volume":"9","author":"JA Gubbels","year":"2010","unstructured":"Gubbels JA, Felder M, Horibata S, Belisle JA, Kapur A, Holden H, et al. MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells. Mol Cancer. 2010;9:11.","journal-title":"Mol Cancer"},{"key":"1967_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1757-2215-2-13","volume":"2","author":"D Gupta","year":"2009","unstructured":"Gupta D, Lis CG. Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature. J Ovarian Res. 2009;2:13.","journal-title":"J Ovarian Res"},{"issue":"1","key":"1967_CR21","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1136\/ijgc-2022-003985","volume":"33","author":"MA Angeles","year":"2023","unstructured":"Angeles MA, Spagnolo E, Cabarrou B, Perez-Benavente A, Gil Moreno A, Guyon F, et al. Impact of pattern of recurrence on post-relapse survival according to surgical timing in patients with advanced ovarian cancer. Int J Gynecol Cancer. 2023;33(1):50\u20136.","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"1967_CR22","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.ygyno.2020.02.022","volume":"157","author":"T Levy","year":"2020","unstructured":"Levy T, Migdan Z, Aleohin N, Ben S, Peled O, Tal O, et al. Retroperitoneal lymph node recurrence of epithelial ovarian cancer: prognostic factors and treatment outcome. Gynecol Oncol. 2020;157(2):392\u20137.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"1967_CR23","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ygyno.2013.06.020","volume":"131","author":"M Petrillo","year":"2013","unstructured":"Petrillo M, Fagotti A, Ferrandina G, Fanfani F, Costantini B, Vizzielli G, et al. Ovarian cancer patients with localized relapse: clinical outcome and prognostic factors. Gynecol Oncol. 2013;131(1):36\u201341.","journal-title":"Gynecol Oncol"},{"key":"1967_CR24","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ejogrb.2020.04.049","volume":"249","author":"R Delangle","year":"2020","unstructured":"Delangle R, Rossard L, Cirier J, Delvallee J, Bendifallah S, Touboul C, et al. Isolated lymph node recurrence in epithelial ovarian cancer: recurrence with better prognosis? Eur J Obstet Gynecol Reprod Biol. 2020;249:64\u20139.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"1967_CR25","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ijsu.2016.03.039","volume":"29","author":"J Zhou","year":"2016","unstructured":"Zhou J, Sun JY, Wu SG, Wang X, He ZY, Chen QH, et al. Risk factors for lymph node metastasis in ovarian cancer: implications for systematic lymphadenectomy. Int J Surg. 2016;29:123\u20137.","journal-title":"Int J Surg"},{"issue":"2","key":"1967_CR26","doi-asserted-by":"publisher","first-page":"188503","DOI":"10.1016\/j.bbcan.2021.188503","volume":"1875","author":"M Zhang","year":"2021","unstructured":"Zhang M, Cheng S, Jin Y, Zhao Y, Wang Y. Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer. Biochim Biophys Acta Rev Cancer. 2021;1875(2):188503.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"6","key":"1967_CR27","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1080\/01443615.2019.1674264","volume":"40","author":"S Kumar","year":"2020","unstructured":"Kumar S, Srinivasan A, Phillips A, Madhupriya R, Pascoe J, Nevin J, et al. Does sites of recurrence impact survival in secondary cytoreduction surgery for recurrent epithelial ovarian cancer? J Obstet Gynaecol. 2020;40(6):849\u201355.","journal-title":"J Obstet Gynaecol"},{"issue":"9747","key":"1967_CR28","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/S0140-6736(10)61268-8","volume":"376","author":"GJ Rustin","year":"2010","unstructured":"Rustin GJ, van der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05\/EORTC 55955): a randomised trial. Lancet. 2010;376(9747):1155\u201363.","journal-title":"Lancet"},{"issue":"3","key":"1967_CR29","first-page":"608","volume":"2","author":"A Mweempwa","year":"2019","unstructured":"Mweempwa A, Wilson MK. Mechanisms of resistance to PARP inhibitors - an evolving challenge in oncology. Cancer Drug Resist. 2019;2(3):608\u201317.","journal-title":"Cancer Drug Resist"},{"issue":"11","key":"1967_CR30","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1200\/JCO.23.01182","volume":"42","author":"A Tjokrowidjaja","year":"2024","unstructured":"Tjokrowidjaja A, Friedlander ML, Ledermann JA, Coleman RL, Mirza MR, Matulonis UA, et al. Gynecologic cancer intergroup Meta-Analysis Committee. Poor concordance between cancer Antigen-125 and RECIST assessment for progression in patients with Platinum-Sensitive relapsed ovarian cancer on maintenance therapy with a Poly(ADP-ribose) polymerase inhibitor. J Clin Oncol. 2024;42(11):1301\u201310.","journal-title":"J Clin Oncol"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-026-01967-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-026-01967-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-026-01967-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T11:53:22Z","timestamp":1774353202000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13048-026-01967-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1967"],"URL":"https:\/\/doi.org\/10.1186\/s13048-026-01967-5","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"assertion":[{"value":"23 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Research and Ethics Committee of Qilu Hospital of Shandong University (KYLL-202404-045). Investigation was conducted in accordance with ethical standards, the Declaration of Helsinki and Chinese and international guidelines. As a real-world retrospective study, the informed consent was waived, and the results were used for scientific research only.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"113"}}